One way to get an idea of the market sentiment on a stock is to check its rate of institutional ownership. In the case of ...

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Fintel reports that on May 14, 2025, Morgan Stanley downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Shares of Halozyme Therapeutics (HALO) and Jonhson & Johnson (JNJ) are under pressure on Tuesday after Leerink downgraded the stocks to Underperform and Market Perform, respectively. This comes after ...

Halozyme Therapeutics (HALO) stock remains under pressure as Morgan Stanley downgrades the company on Medicare price negotiation concerns. Read more here.

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...

Halozyme Therapeutics posts strong Q1 2025 earnings with 35% revenue growth, robust pipeline, and rising royalties.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...